Issues surrounding tight glycemic control in people with type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 32, Issue 9, 1998, Pages 896-905

  Cerveny, Joli D ^a   Leder, Rachel D ^b   Weart, C Wayne ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes mellitus; Glycemic control; Type 2

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL; TROGLITAZONE;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; INSULIN RESISTANCE; MEDLINE; RANDOMIZED CONTROLLED TRIALS;

EID: 0031710599     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17375     Document Type: Review

References (68)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes in the United States. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 1997.
2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
3. American Diabetes Association. Physician's guide to non-insulin dependent (type II) diabetes: diagnosis and treatment. 3rd ed. Alexandria, VA: American Diabetes Association, Inc., 1994.
4. Olefsky JM. Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitus. Am J Med 1985;79(suppl 3B):1-7.
5. Geiss LS, ed. Diabetes surveillance 1991. Atlanta: US Department of Health and Human Services, Centers for Disease Control National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, 1991.
6. Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Sterm MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Washington, DC: US Government Printing Office (NIH publication no. 95-1468), 1995.
7. Palmburg P, Smith M, Waltman S, Krupin T, Singer P, Burgess D, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981;88:613-8.
8. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85.
9. Ross MA. Neuropathies associated with diabetes. Med Clin North Am 1993;77:111-4.
10. White JR. Strict glycemic control: essential in diabetes mellitus. Pharmaguide to hospital medicine 1994;7(6):1-4,9-10.
11. Clements RS Jr. The polyol pathway, a historical review. Drugs 1986; 32(suppl 2):3-5.
12. Gabby KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973;288:831-6.
13. Clark CM Jr, Lee A. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-7.
14. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
15. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in NID-DM. N Engl J Med 1993;329:977-86.
16. The American Diabetes Association. Position statement: implications of the diabetes control and complications trial. Diabetes Care 1993;16: 1517-20.
17. Ohkubo Y, Kishibkawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
18. American Diabetes Association. Consensus statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19 (suppl 1):S54-S61.
19. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
20. Kannel WB, McGee DL. Diabetes and cardiovascular disease. JAMA 1979;241:2-35-8.
21. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. Ann Intern Med 1977;87:393-7.
22. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75: 894-903.
23. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
24. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990;131:443-53.
25. Elliot TG, Viberti G. Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. Baillieres Clin Endocrinol Metab 1993;7:1079-102.
26. Kissebah AH, Freeman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989;73:111-38.
27. Bakris GL. Pathogenesis of hypertension in diabetes. Diabetes Rev 1995;3:460-76.
28. Howard BV. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995; 3:423-32.
29. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
30. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514-20.
31. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1988;37(suppl 1):1-9.
32. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 1994;37:948-52.
33. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy. Diabetologia 1994;37:956-8.
34. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41.
35. Pyorala K, Savolainen E, Kaulola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki policemen study population. Acta Med Scand 1985;701(suppl):38-52.
36. Fontbonne A, Tchobroutsky G, Eschwege E, Richards JL, Claude JR, Rosselin GE, et al. Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. Paris Prospective Study. Int J Obes 1988; 12:557-65.
37. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991;14:461-9.
38. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60.
39. Cullen K, Stenhouse NS, Wearne KL, Wellborn TA. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia - 12-year study. J Chron Dis 1983;36: 371-7.
40. Folsom AR, Syklo M, Stevens J, Liao F, Smith R, Eckfeldt JH, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. Diabetes Care 1997;20:935-42.
41. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
42. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline results. Diabetes 1970;19:747-72.
43. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789-830.
44. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1975;24(suppl 1):65-184.
45. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982;31 (suppl 5):1-81.
46. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. Diabetes Care 1992;15:1560-71.
47. Abraira C, Colwell J, Nuttal FQ, Sawin CT, Johnson-Nagel N, Comstock JP, et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Results of a feasibility trial. Diabetes Care 1995;18:1113-23.
48. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock J, et al. Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial. Arch Intern Med 1997;157:181-8.
49. UK Prospective Diabetes Study Group: UKPDS. VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.
50. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
51. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 1998;21(suppl 1):S20-2.
52. Henry RR, Genuth S. Forum one: current recommendations about intensification of metabolic control in NIDDM. Ann Intern Med 1996;124(1 pt 2):175-7.
53. National High Blood Pressure Education Program Working Group. Working group report on hypertension in diabetes. Hypertension 1994; 23:145-58.
54. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21(suppl 1):S36-9.
55. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 1998;21(suppl 1):S45-6.
56. Kelly DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995;3:366-76.
57. Sharma AM. Effects of nonpharmacological intervention on insulin sensitivity. J Cardiovasc Pharmacol 1992;20(suppl 11):S27-34.
58. American Diabetes Association. Consensus statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18: 1510-8.
59. Haupt E, Kruck B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulfonylureas and metformin. Diabetes Metab 1991;17:224-31.
60. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lingarde F, Melander A, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-9.
61. Yki-Jarvinen H, Kauppila M, Kujansun E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
62. De Fronzo RA, Goodman AM, and the Multi-center Metformin Study Group. Efficacy in metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
63. Ghazzi M, Mitchell LR, Venable T, The Troglitazone Study Group, Randall Whitcomb. Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea (abstract). Diabetes 1997;46(suppl 1):44A.
64. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Shulman GI. Efficacy and metabolic effects of troglitazone and metformin in NIDDM (abstract). Diabetes 1997;46(suppl 1):34A.
65. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
66. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wahlen-Boll E, Melander A, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991;14:724-7.
67. Stenman S, Lelander A, Groop PH, Groop LC. What is the benefit of increasing sulfonylurea dose? Ann Intern Med 1993;118:169-72.
68. Wahlin-Boll E, Sartor G, Melander A, Schersten B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982;22: 21-5.